Moderna (NASDAQ: MRNA) has been one of the superstars of the coronavirus vaccine race — from a share performance and vaccine development perspective.

Moderna slid as the market crashed in March, but the stock quickly recovered. As they say, timing is everything. Moderna announced the launch of clinical trials for its vaccine candidate a few days after the market’s plunge deepened. The shares then surged 48% over three trading sessions. So, if you had invested $10,000 in Moderna during the crash, how much money would you have now? Let’s take a look.

Guess how much Moderna stock is trading for at the time of this writing? More than $63. (And that’s off its high of nearly $95 in July.) If you’d invested $10,000 in the shares at the March low, you would now have $29,547. You would have held on through the positives, such as when the company reported encouraging interim data from its phase 1 trial and announced as much as $2.48 billion in U.S. government funding.

Another hard time for Moderna came with news reports in early July that the start of the company’s phase 3 trial could be delayed. But Moderna maintained its publicly announced promise to begin the study during that month. It launched on July 27.

Is now too late to invest?

So, now, should you stay invested? And if you haven’t yet purchased Moderna shares, is it too late? Moderna still represents opportunity. From a timeline perspective, the company is one of the leaders in the coronavirus vaccine race. Of the 33 programs in clinical studies, Moderna is among the eight involved in phase 3 trials.